Guangdong Baoli Pharmaceutical's 4 Billion-Dose Formulation Project Commences Construction, Boosting Logistics and Supply Chain

Deep News
Jan 22

The Guangdong Baoli Pharmaceutical annual 4 billion tablet (capsule) formulation project has officially commenced construction in Shatang Town, Kaiping City, Jiangmen. Located in Shatang Town, Kaiping City, Jiangmen, Guangdong Province, the project is being constructed by CCCC Fourth Harbor Engineering Bureau Co., Ltd. and involves the planned development of three major sections: production support facilities, administrative support buildings, and outdoor ancillary infrastructure. These will encompass core functional areas such as a combined workshop, a comprehensive formulation workshop, a penicillin workshop, and a hazardous materials warehouse.

Beyond its production scale, the project's "engine" effect is also reflected in its high-standard factory buildings and comprehensive supporting facilities, which are expected to attract more upstream and downstream supporting enterprises, R&D institutions, and high-end talent to gather in Kaiping. It is anticipated that this will drive the formation of a complete industrial chain, ranging from active pharmaceutical ingredient supply and excipient production to packaging materials, R&D services, and logistics distribution, thereby upgrading the regional biopharmaceutical industry ecosystem towards greater vitality and resilience.

Liu Chao, Deputy Head of the Project Engineering Department at CCCC Fourth Harbor Engineering Bureau, stated that the project team will strictly adhere to the construction requirements of "high standards, high quality, and high efficiency." A seasoned management team and a pool of technical experts will be assembled to meticulously organize scientific planning and strengthen quality and safety control throughout the entire process, striving to complete the project as soon as possible.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10